Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab/Tuvonralimab + albumin-paclitaxel in 2nd-line advanced gastric/GEJ cancer
NCT07139587Phase 2Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07139587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07139587.